Navigation Links
Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinson's Disease
Date:9/2/2009

OMAHA, Neb. and HOUSTON, Sept. 2 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications. The study demonstrates the usefulness of a protein biomarker panel to distinguish Parkinson's disease (PD) patients from age-matched normal controls independent of the severity of symptoms, using clinical blood serum samples.

The analytic technology forms the basis for the NuroPro(R)PD test for PD being commercialized by Transgenomic as per a licensing/collaboration agreement with Power3 Medical signed in early 2009. The publication of the peer-reviewed article is a significant validation milestone in the ongoing clinical development of the NuroProPD diagnostic assay.

The article describes the use of analytically validated quantitative 2D gel electrophoresis to identify protein biomarkers for diagnosing PD using serum from routinely collected blood samples. 57 protein biomarkers, which had been discovered using retrospective blood serum samples from various neurodegenerative diseases, were then applied specifically to PD in a prospective clinical investigation using freshly collected blood serum from PD patients and age-matched normal controls. A multi-variate statistical method, stepwise linear discriminant analysis, selected a combination of 21 of the biomarkers as optimal to distinguish PD patients from controls. When applied to the PD samples, the 21-protein set had sensitivity of 93.3% (52 of 56 PD correctly classified) and specificity of 92.9% (28 of 30 controls correctly classified); 15 of 15 patients with mild and 28 of 30 with moderate to severe symptoms were correctly classif
'/>"/>

SOURCE Transgenomic, Inc.; Power3 Medical Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2009 Results
2. Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
3. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
4. Transgenomic, Inc. Announces Appointment of New Board Members
5. Transgenomic, Inc. Reports First Quarter 2009 Results
6. Reminder: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
7. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
8. Webcast Alert: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
9. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
10. Polycystic Kidney Disease Assay at Cornell University Uses Transgenomics Surveyor Nuclease & WAVE Technology
11. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... 2014   Synthetic Biologics, Inc. (NYSE MKT: ... serious infections and diseases, announced today that the U.S. ... Allowance for a composition of matter patent application that ... program, SYN-004. This is Synthetic Biologics, first allowed patent ... adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... Genencor,s Senior Management Team, ROCHESTER, N.Y., Oct. ... announced that Dr. Glenn E. Nedwin will join ... effective Oct. 1, 2007. As a,member of the ... the,division,s activities in Grain Processing (which includes current ...
... CEO Glenn A. Oclassen to Join Sleep Experts in Panel Hosted by ... ... 1 Transcept Pharmaceuticals,Inc. today announced that Glenn A. Oclassen, President and ... the Natixis Bleichroeder "Hidden Gems" Healthcare Conference. Date: Monday, ...
... BRUSSELS, October 1 Austria now has the ... 2007 Euro,Health Consumer Index (EHCI). The EHCI compares ... Norway and Switzerland, from a,consumer-friendly point of view, ... 2005 winners the Netherlands, with 2006 winner,France in ...
Cached Biology Technology:Genencor Appoints New Executive Vice President - Technical Enzymes 2Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel 2European Union has 'Three-Speed' Healthcare System - Many Countries Lagging in Reform 2
(Date:10/14/2014)... discovered a new kind of stem cell that can become ... blood vessels, according to a study published today in the ... a cell type contradicts current theory on how organs arise ... to origins of, and future treatment for, liver cancer., Thanks ... a complex being made up of more than 200 cell ...
(Date:10/14/2014)... Scientists from The Scripps Research Institute (TSRI) have been ... (NIH) to lead an investigation of Lassa fever virus, ... The study aims to understand how Lassa fever virus ... survive the inflection. , "The ultimate goal is ... Lassa fever virus causes disease and develop new treatments ...
(Date:10/14/2014)... team of researchers, led by the Chinese Academy of ... Nature Genetics a brief genomic history of tomato ... tomato plant. , The C.M. Rick Tomato Genetics Resource ... this study by providing seed of both cultivated tomato ... builds on the first tomato genome sequence completed just ...
Breaking Biology News(10 mins):Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... Sathyanaryanan Puthanveettil, an assistant professor on the Florida ... a pair of notable grants to study a critical ... receive $225,000 over three years from the prestigious Whitehall ... a motor protein called kinesin. In this study, he ...
... most commonly diagnosed cancer in the United States and often ... on ways to improve their understanding of the disease. ... at the San Diego Marriott Marquis & Marina during Jan. ... of Lung Cancer: Biology, Therapy and Personalized Medicine. ...
... WASHINGTON -- The draft 10-year strategic plan for ... shapes and coordinates climate and related global environmental change ... federal government -- is "evolving in the right direction," ... says a new report from the National Research Council. ...
Cached Biology News:Scripps Research Scientist wins pair of grants to study critical component of memory 2Lung cancer conference to focus on new diagnostic techniques, potential treatments 2New report reviews plan for US Global Change Research Program 2
Polyclonal Antibody to HADHB...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
A431 cells stimulated with EGF Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: